9P - Serum Intercelllular adhesion molecule -1 level in patients of breast cancer and its association with Carbohydrate antigen 15-3 and TNM stage

Date 04 May 2017
Event IMPAKT 2017
Session Welcome reception and Poster Walk
Topics Breast Cancer
Staging Procedures (clinical staging)
Pathology/Molecular Biology
Basic Scientific Principles
Basic Principles in the Management and Treatment (of cancer)
Presenter A S Saumya
Authors A.S. Saumya, K. Agarwal
  • Pathology, Lady hardinge medical college, 110001 - Delhi/IN




The diagnosis of breast cancer at an earlier stage allows earlier treatment and better prognosis.The need exists for more practical and sensitive laboratory methods which can indicate the presence of any neoplasm and provide a quantitative estimate of changes associated with growth, spread or dissemination and therapy.

Many serum marker been developed as result are obtain in shorter span of time. CA 15-3 is a high molecular mass glycoprotein. ICAM-1 is adhesion molecule and belongs to the immunoglobin superfamily .Intercellular adhesion molecule play role in process of invasion and development of metastasis. The increased serum concentration of these marker is associated with large burden of disease and poor prognosis .


Serum samples from 50 trucut biopsy proven non treated cases of breast carcinoma and 50 age & sexmatched healthy controls were included during December 2013 to March 2015 at Lady Hardinge Medical College .Serum levels of ICAM-1 and CA15-3 were measured b by ELISA.


The serum levels of serum ICAM-1 ranged from 143ng/ml to 1100ng/ml with mean value 502.58±247.63 ng/ml and the serum level of CA 15-3 ranged from 19 U/ml to 200 U/ml with mean value 82.06±48.47 U/ml. There was significant difference in the mean serum ICAM-1 and CA 15-3 levels between patients of breast carcinoma and healthy controls both with p value (p<0.001). There was significant difference between the mean concentration of sICAM-1 and serum CA 15-3 when T4 was compared with T1,T2,T3. Serum ICAM-1 and CA 15-3 concentration were significantly higher in patients with lymph node positive tumor as compared to lymph node negative tumor. Stage III had significantly higher levels of serum ICAM-1 and serum CA 15-3 compared to Stage I and Stage II . The mean serum concentration ICAM-1 and CA15-3 were higher in ER ,PR positive patients. The mean serum concentration ICAM-1 and CA 15-3 were higher in Her-2 neu negative patients.


The level of serum ICAM -1 and CA 15-3 showed rising level in patient with increasing tumor size, lymph node positivity, stage Bloom Richardson grade. Both the marker had linear correlation with tumor size, lymph node stage and grade.

Clinical trial identification

Not Applicable